cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cymabay Therapeutics Inc
24 own
39 watching
Current Price
$32.16
$-0.03
(-0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
788.38M
52-Week High
52-Week High
32.24000
52-Week Low
52-Week Low
7.26100
Average Volume
Average Volume
3.43M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization788.38M
icon52-Week High32.24000
icon52-Week Low7.26100
iconAverage Volume3.43M
iconDividend Yield--
iconP/E Ratio--
What does the Cymabay Therapeutics Inc do?
Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its key clinical development candidates comprise MBX-8025, a selective agonist that is in a third Phase II clinical trial in patients with primary biliary cholangitis; and Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Read More
How much money does Cymabay Therapeutics Inc make?
News & Events about Cymabay Therapeutics Inc.
Ticker Report
7 months ago
CymaBay Therapeutics, Inc. (NASDAQ:CBAY Free Report) General Paul T. Quinlan sold 5,000 shares of the firms stock in a transaction that occurred on Friday, June 30th. The shares were sold at an average price of $10.05, for a total value of $50,250.00. The transaction was disclosed in ...
TipRanks Financial Blog
7 months ago
LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on CymaBay Therapeutics (CBAY Research Report) today and set a price target of $1...
Stock Options Channel
7 months ago
Investors eyeing a purchase of CymaBay Therapeutics Inc (CBAY) shares, but tentative about paying the going market price of 7.95/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2024...
PR Newswire
8 months ago
CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC) Correlates with Alleviation of Self-Reported Pruritus and Reduction in Serum IL-31 Levels CymaBay Therapeutics Presents Data Showing Seladelpar Treatment in Primary Biliary Cholangitis (PBC...
Globe Newswire
10 months ago
NEWARK, Calif., April 21, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from the ENHANCE phase 3 ...
Frequently Asked Questions
Frequently Asked Questions
What is Cymabay Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Cymabay Therapeutics Inc shares?
plus_minus_icon
How can I buy Cymabay Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Cymabay Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cymabay Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Cymabay Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Cymabay Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cymabay Therapeutics Inc?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cymabay Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$32.16
$-0.03
(-0.09%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00